Combination neratinib (HKI-272) and paclitaxel therapy in patients with HER2-positive metastatic breast cancer
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Combination neratinib (HKI-272) and paclitaxel therapy in patients with HER2-positive metastatic breast cancer
Authors
Keywords
-
Journal
BRITISH JOURNAL OF CANCER
Volume 108, Issue 10, Pages 1985-1993
Publisher
Springer Nature
Online
2013-05-01
DOI
10.1038/bjc.2013.178
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Abstract P3-14-05: Safety and Efficacy of Neratinib (HKI-272) Plus Vinorelbine in the Treatment of Patients with ErbB2+ Metastatic Breast Cancer Pretreated with Anti-HER2 Therapy:
- (2011) E Staroslawska et al. CANCER RESEARCH
- Phase I Study of Navitoclax (ABT-263), a Novel Bcl-2 Family Inhibitor, in Patients With Small-Cell Lung Cancer and Other Solid Tumors
- (2011) Leena Gandhi et al. JOURNAL OF CLINICAL ONCOLOGY
- Cancer Statistics, 2010
- (2010) A. Jemal et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Phase I Study of Everolimus Plus Weekly Paclitaxel and Trastuzumab in Patients With Metastatic Breast Cancer Pretreated With Trastuzumab
- (2010) Fabrice Andre et al. JOURNAL OF CLINICAL ONCOLOGY
- Neratinib, an Irreversible ErbB Receptor Tyrosine Kinase Inhibitor, in Patients With Advanced ErbB2-Positive Breast Cancer
- (2010) Harold J. Burstein et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized Study of Lapatinib Alone or in Combination With Trastuzumab in Women With ErbB2-Positive, Trastuzumab-Refractory Metastatic Breast Cancer
- (2010) Kimberly L. Blackwell et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase III Randomized Study Comparing Docetaxel Plus Trastuzumab With Vinorelbine Plus Trastuzumab As First-Line Therapy of Metastatic or Locally Advanced Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: The HERNATA Study
- (2010) Michael Andersson et al. JOURNAL OF CLINICAL ONCOLOGY
- A Single-Arm Phase II Trial of First-Line Paclitaxel in Combination with Lapatinib in HER2-Overexpressing Metastatic Breast Cancer
- (2010) Agnieszka Jagiello-Gruszfeld et al. ONCOLOGY
- Lapatinib monotherapy in patients with relapsed, advanced, or metastatic breast cancer: efficacy, safety and biomarker results from Japanese patients phase II studies
- (2009) M Toi et al. BRITISH JOURNAL OF CANCER
- Role of Cell Cycle in Epidermal Growth Factor Receptor Inhibitor-Mediated Radiosensitization
- (2009) A. Ahsan et al. CANCER RESEARCH
- A Phase I Study with Neratinib (HKI-272), an Irreversible Pan ErbB Receptor Tyrosine Kinase Inhibitor, in Patients with Solid Tumors
- (2009) K.-K. Wong et al. CLINICAL CANCER RESEARCH
- Weekly Paclitaxel and Trastuzumab as a First-Line Therapy in Patients with HER2-Overexpressing Metastatic Breast Cancer: Magnitude of HER2/neu Amplification as a Predictive Factor for Efficacy
- (2009) Hye-Suk Han et al. JOURNAL OF KOREAN MEDICAL SCIENCE
- A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses
- (2008) David Cameron et al. BREAST CANCER RESEARCH AND TREATMENT
- Randomized Phase III Trial of Weekly Compared With Every-3-Weeks Paclitaxel for Metastatic Breast Cancer, With Trastuzumab for all HER-2 Overexpressors and Random Assignment to Trastuzumab or Not in HER-2 Nonoverexpressors: Final Results of Cancer and Leukemia Group B Protocol 9840
- (2008) Andrew D. Seidman et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase III, Double-Blind, Randomized Study Comparing Lapatinib Plus Paclitaxel With Placebo Plus Paclitaxel As First-Line Treatment for Metastatic Breast Cancer
- (2008) Angelo Di Leo et al. JOURNAL OF CLINICAL ONCOLOGY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started